Anti-Human Adiponectin (NT)

Purified Recombinant Human Adiponectin (>98%)

This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.

This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Next Day Ambient

Rabbit Anti-Human Adiponectin recognizes an epitope near the N-terminus of Human, Mouse and Rat Adiponectin. This polyclonal antibody was purified using affinity chromatography.

Adiponectin, also known as Acrp30, is an adipocyte-derived protein with wide ranging paracrine and endocrine effects on metabolism and inflammation. It is induced during adipocyte differentiation, and its secretion is stimulated by insulin. It promotes adipocyte differentiation, fatty acid catabolism, and insulin sensitivity and is negatively correlated with obesity, type 2 diabetes, and atherogenesis. In this context, Adiponectin is an anti-inflammatory agent, but it exerts pro-inflammatory effects in nonmetabolic disorders such as rheumatoid arthritis and inflammatory bowel disease. Adiponectin interacts with the receptors AdipoR1 and AdipoR2, calreticulin, and Cadherin-13/T-Cadherin, as well as with several growth factors. Mature human Adiponectin shares 83% and 85% amino acid (aa) sequence identity with mouse and rat Adiponectin, respectively. The glycosylation of four hydroxylated lysine residues in the collagenous domain is required for the intracellular formation of HMW complexes. The various multimeric forms of Adiponectin exhibit distinct tissue specific and gender specific profiles and activities.

PN:A278 is applicable as a control peptide for blocking antibody binding in Western blotting.

1. Fantuzzi, G. (2005) J. Allergy Clin. Immunol. 115:911
2. Rota, PA. et al. (2003) Science 300:1394
3. Wong, GW. et al. (2004) Proc. Natl. Acad. Sci. USA 101:10302
4. Li, W. et al. (2003) Nature 426:450